
Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing.
The round was led by the company’s incubator, RA Capital Management, together with important healthcare investors including Venrock Healthcare Capital Partners, Deep Track Capital and Boxer Capital.